TY  - GEN
AU  - Lee,Jii Bum
AU  - Kim,Han Sang
AU  - Jung,Inkyung
AU  - Shin,Sang Joon
AU  - Beom,Seung Hoon
AU  - Chang,Jee Suk
AU  - Koom,Woong Sub
AU  - Kim,Tae Il
AU  - Hur,Hyuk
AU  - Min,Byung Soh
AU  - Kim,Nam Kyu
AU  - Park,Sohee
AU  - Jeong,Seung-Yong
AU  - Baek,Jeong-Heum
AU  - Kim,Seon Hahn
AU  - Lim,Joon Seok
AU  - Lee,Kang Young
AU  - Ahn,Joong Bae
TI  - Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial
SN  - 1745-6215
PY  - 2021///0118
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Chemoradiotherapy
KW  - methods
KW  - Chemotherapy, Adjuvant
KW  - Clinical Trials, Phase II as Topic
KW  - Disease-Free Survival
KW  - Dose-Response Relationship, Drug
KW  - Drug Administration Schedule
KW  - Fluorouracil
KW  - Humans
KW  - Leucovorin
KW  - Multicenter Studies as Topic
KW  - Neoadjuvant Therapy
KW  - Neoplasm Invasiveness
KW  - Neoplasm Staging
KW  - Organoplatinum Compounds
KW  - Preoperative Care
KW  - Prognosis
KW  - Prospective Studies
KW  - Randomized Controlled Trials as Topic
KW  - Rectal Neoplasms
KW  - drug therapy
KW  - Republic of Korea
KW  - Survival Analysis
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial Protocol; Comparative Study; Journal Article
UR  - https://doi.org/10.1186/s13063-020-04266-6
ER  -